0000000000056676

AUTHOR

Luis J. V. Galietta

showing 4 related works from this author

An overview on chemical structures as ΔF508-CFTR correctors

2019

Deletion of phenylalanine at position 508 (F508del) in the CFTR protein, is the most common mutation causing cystic fibrosis (CF). F508del causes misfolding and rapid degradation of CFTR protein a defect that can be targeted with pharmacological agents termed “correctors”. Correctors belong to various chemical classes but are generally small molecules based on nitrogen sulfur or oxygen heterocycles. The mechanism of action of correctors is generally unknown but there is experimental evidence that some of them can directly act on mutant CFTR improving folding and stability. Here we overview the characteristics of the various F508del correctors described so far to obtain indications on key ch…

Protein FoldingCystic FibrosisCFTR correctorMutantCystic Fibrosis Transmembrane Conductance RegulatorPyrimidinonesmedicine.disease_cause01 natural sciencesF508del-CFTR03 medical and health sciencesMutant proteinDrug DiscoverymedicineAnimalsHumansCFTR030304 developmental biologyPharmacology0303 health sciencesMutationCFTR correctorsbiology010405 organic chemistryChemistryOrganic ChemistryCFTR; CFTR correctors; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; F508del-CFTR; Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mutation; Protein Folding; Pyrimidinones; ThiazolesGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaSmall moleculeCystic fibrosis transmembrane conductance regulator0104 chemical sciencesCell biologyThiazolesMechanism of actionCystic fibrosiMutationbiology.proteinmedicine.symptomProtein Aδf508 cftrEuropean Journal of Medicinal Chemistry
researchProduct

Current development of CFTR potentiators in the last decade

2020

Cystic fibrosis (CF) is a genetic disorder produced by the loss of function of CFTR, a main chloride channel involved in transepithelial salt and water transport. CFTR function can be rescued by small molecules called "potentiators" which increase gating activity of CFTR on epithelial surfaces. High throughput screening (HTS) assays allowed the identification of new chemical entities endowed with potentiator properties, further improved through medicinal chemistry optimization. In this review, the most relevant classes of CFTR potentiators developed in the last decade were explored, focusing on structure-activity relationships (SAR) of the different chemical entities, as a useful tool for t…

congenital hereditary and neonatal diseases and abnormalitiesHigh-throughput screeningGlycineComputational biologyQuinolonesVX-770Aminophenols01 natural sciencesCystic fibrosisCystic fibrosisSmall Molecule LibrariesStructure-Activity Relationship03 medical and health sciencesDrug DiscoverymedicineHumansCFTR potentiatorCFTRLoss function030304 developmental biologyPharmacology0303 health sciencesWater transportbiology010405 organic chemistryChemistryOrganic ChemistryCFTR potentiatorsBiological activityGeneral MedicineTriazolesPotentiatormedicine.diseaseCystic fibrosis transmembrane conductance regulator0104 chemical sciencesCystic fibrosiMutationChloride channelbiology.proteinCystic fibrosis transmembrane conductance regulatorEuropean Journal of Medicinal Chemistry
researchProduct

Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.

2021

Cystic fibrosis (CF) is a genetic disease caused by mutations that impair the function of the CFTR chloride channel. The most frequent mutation, F508del, causes misfolding and premature degradation of CFTR protein. This defect can be overcome with pharmacological agents named “correctors”. So far, at least three different classes of correctors have been identified based on the additive/synergistic effects that are obtained when compounds of different classes are combined together. The development of class 2 correctors has lagged behind that of compounds belonging to the other classes. It was shown that the efficacy of the prototypical class 2 corrector, the bithiazole corr-4a, could be impr…

Yellow fluorescent proteinProtein FoldingCystic FibrosisMutantPharmaceutical ScienceCystic Fibrosis Transmembrane Conductance RegulatorCarboxamidemedicine.disease_cause01 natural sciencesAnalytical Chemistrychemistry.chemical_compoundMutant ProteinDrug DiscoveryMoietyCFTR potentiatorCFTRchemistry.chemical_classification0303 health sciencesMutationbiologyChemistryChemistry (miscellaneous)Chloride channelMolecular MedicineHumanStereochemistrymedicine.drug_classCFTR correctorArticleF508del-CFTRlcsh:QD241-44103 medical and health scienceslcsh:Organic chemistrymedicineHumansBenzodioxolesPhysical and Theoretical ChemistryThiazoleCystic Fibrosi030304 developmental biology010405 organic chemistryOrganic ChemistryAminoimidazole Carboxamide0104 chemical sciencesThiazolesMutationbiology.proteinMutant ProteinsBenzodioxoleTricyclicMolecules (Basel, Switzerland)
researchProduct

Furocoumarins as multi-target agents in the treatment of cystic fibrosis.

2019

Multi-target molecular entities, offer a path to progress both in understanding causes of disease and in defining effective small molecule treatments. Coumarin and its derivatives belong to an important group of natural compounds with diverse biological properties. They are found in vegetables and plants for which literature reports thousands of publications for the great variety of biological applications among which the photoprotective effects, thus being considered multi-targeting agents. Their furan condensed analogues constitute the family of furocoumarins, less represented in the literature, endowed with photosensitizing properties and often used for the treatment of skin diseases suc…

Cystic FibrosisFurocoumarinComputational biologyCystic fibrosisStructure-Activity RelationshipMulti targetCoumarinsBiological propertyFurocoumarinsDrug DiscoverymedicineCystic fibrosis (CF)HumansCFTR modulatorPharmacologyDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryGeneral Medicinemedicine.diseaseCFTR modulatorsMulti-target agentsSmall moleculeFurocoumarinsCFTR modulators; Cystic fibrosis (CF); Furocoumarins; Multi-target agentsEuropean journal of medicinal chemistry
researchProduct